Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management

被引：12

作者：

Blum L. ^{[1
]}

Cummings K. ^{[1
]}

Goulet J.A. ^{[1
]}

Perdue A.M. ^{[1
]}

Mauffrey C. ^{[2
]}

Hake M.E. ^{[1
]}

机构：

[1] Department of Orthopaedic Surgery, University of Michigan, 2912 Taubman Center, SPC 5328, 1500 E. Medical Center Dr., Ann Arbor, 48109, MI

[2] Department of Orthopaedic Surgery, Denver Health Medical Center, Denver, 80204, CO

来源：

European Journal of Orthopaedic Surgery & Traumatology | 2016年 / 26卷 / 4期

关键词：

Atypical femur fracture; Bisphosphonate therapy; Osteoporosis; Stress fractures;

D O I：

10.1007/s00590-016-1742-6

中图分类号：

学科分类号：

摘要：

Osteoporosis is a growing problem that is projected to affect more than 50% of American adults by 2020. Bisphosphonate therapy is currently the primary mode of treating osteoporosis in this population. While bisphosphonate therapy has been successful in increasing bone mineral density, data has shown an increased risk of atypical femur fractures with prolonged therapy. Atypical femur fractures are characterized by low-energy or atraumatic injuries that occur in the subtrochanteric region. They originate on the medial cortex, travel transversely, and typically have little or no comminution. Conservative therapy is indicated for patients with incomplete fractures without prodromal symptoms. Patients with incomplete fractures and significant prodromal symptoms or visible fracture line on radiographs, those who have failed conservative management, and those with complete fractures should be treated with intramedullary nail fixation. Evaluation should involve imaging of the contralateral femur. Teriparatide therapy may be considered for patients without contraindications. While the incidence of these fractures is low, it is likely that these rates will increase with the aging population and increased prevalence of patients being treated with bisphosphonate therapy. © 2016, Springer-Verlag France.

引用

页码：371 / 377

页数：6

共 29 条

[1]

US Department of Health and Human Services, Bone health and osteoporosis: a report of the Surgeon General, (2004)

[2]

Siris E.S., Pasquale M.K., Wang Y., Watts N.B., Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001–2008, J Bone Miner Res, 26, 1, pp. 3-11, (2011)

[3]

Gamsjaeger S., Buchinger B., Zwettler E., Recker R., Black D., Gasser J.A., Et al., Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid, J Bone Miner Res, 26, 1, pp. 12-18, (2011)

[4]

Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Et al., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 9041, pp. 1535-1541, (1996)

[5]

Feller R.J., Cohen E., Born C.T., Hayda R., Atypical fractures of the femur: evaluation and treatment, JBJS Rev, 3, 3, pp. 1-8, (2015)

[6]

Shane E., Burr D., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., Cosman F., Curtis J.R., Dell R., Dempster D.W., Ebeling P.R., Einhorn T.A., Genant H.K., Geusens P., Klaushofer K., Lane J.M., McKiernan F., McKinney R., Ng A., Nieves J., O'Keefe R., Papapoulos S., Howe T.S., van der Meulen M.C., Weinstein R.S., Whyte M.P., Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research, J Bone Miner Res, 29, 1,

[7]

Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., Cosman F., Curtis J.R., Dell R., Dempster D., Einhorn T.A., Genant H.K., Geusens P., Klaushofer K., Koval K., Lane J.M., McKiernan F., McKinney R., Ng A., Nieves J., O'Keefe R., Papapoulos S., Sen H.T., van der Meulen M.C., Weinstein R.S., Whyte M., American society for bone and mineral research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American society for bone a

[8]

Feldstein A.C., Black D., Perrin N., Rosales A.G., Friess D., Boardman D., Et al., Incidence and demography of femur fractures with and without atypical features, J Bone Miner Res, 27, 5, pp. 977-986, (2012)

[9]

Schilcher J., Aspenberg P., Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate, Acta Orthop, 80, 4, pp. 413-415, (2009)

[10]

Lo J.C., Huang S.Y., Lee G.A., Khandewal S., Provus J., Ettinger B., Et al., Clinical correlates of atypical femoral fracture, Bone, 51, 1, pp. 181-184, (2012)

← 1 2 3 →